Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - April 2025

Vendors are growing, and product and service offerings are expanding.

The Hot Market for Cold Chain Services

How artificial intelligence tools are helping to optimize the pharmaceutical transport process.

An AI-Pharma Transport Collaboration

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit

Videos

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.

LogiPharma Europe 2025: Three Ways to Turn Sustainability Pledges Into Progress

Articles

The program measures a company’s air cargo supply chain efforts when it comes to quality, safety, and compliance.

IATA CEIV Celebrates a Decade of Enhancing Air Cargo Efficiency 

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.

Analyzing Tariffs’ Effect on the Biopharmaceutical Supply Chain

Pharma Pulse 4/23/25: Regeneron, Roche Launch Major US Expansion Plans to Meet Growing Demand for Biologics and Innovation, Trump Assessing Slashing US Drug Prices to International Levels

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares insights on how sustainability has evolved from a compliance requirement to a key business strategy, driving operational efficiencies, innovation, and long-term growth.

LogiPharma Europe 2025: Driving Business Success Through Sustainability

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

Reducing Polypharmacy in Older Adults

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

The Impact of Pharma Tariffs on Drug Shortages

Pharma Pulse 4/22/25: FDA Moves to Block Biopharma Employees From Serving on Advisory Committees, FDA Cuts Outlined in Draft HHS Budget

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies. 

Thermo Fisher Scientific Unveils Advanced Therapies Collaboration Center 

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, comments on the steps needed to achieve Drug Supply Chain Security Act compliance.

Featured Content

Pharmaceutical Commerce - April 2025

The Hot Market for Cold Chain Services

An AI-Pharma Transport Collaboration

Popping the Gross-to-Net Bubble, Part III: The Pharmacy Benefit